Pioneering studies of histone deacetylase inhibitors in myeloma: signals of activity set the stage for combination therapy trials

Affiliations

¹ Department of Haematology, Peter MacCallum Cancer Centre and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia. miles.prince@petermac.org

Comment

H Miles Prince. Leuk Lymphoma. 2012 Sep.

. 2012 Sep;53(9):1658-9.

doi: 10.3109/10428194.2012.658571. Epub 2012 Feb 13.

¹ Department of Haematology, Peter MacCallum Cancer Centre and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia. miles.prince@petermac.org

No abstract available

Comment on

Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma.
Wolf JL, Siegel D, Goldschmidt H, Hazell K, Bourquelot PM, Bengoudifa BR, Matous J, Vij R, de Magalhaes-Silverman M, Abonour R, Anderson KC, Lonial S. Wolf JL, et al. Leuk Lymphoma. 2012 Sep;53(9):1820-3. doi: 10.3109/10428194.2012.661175. Epub 2012 Mar 1. Leuk Lymphoma. 2012. PMID: 22288662 Clinical Trial. No abstract available.